Utah Medical Products Inc.
Find Ratings ReportsSales and net income have dropped, underperforming the average competitor within its subsector. UTAH MEDICAL PRODUCTS INC is extremely liquid. Currently, the Quick Ratio is 20.73 which clearly shows the ability to cover any short-term cash needs. UTMD managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has increased by 12.30% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 12.33 | 13.57 |
EBITDA ($mil) | 0.0 | 6.81 |
EBIT ($mil) | 0.0 | 5.07 |
Net Income ($mil) | 4.29 | 4.56 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 92.87 | 75.05 |
Total Assets ($mil) | 135.46 | 123.87 |
Total Debt ($mil) | 0.3 | 0.4 |
Equity ($mil) | 128.31 | 114.25 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 0.0 | 62.56 |
EBITDA Margin | 0.0 | 50.15 |
Operating Margin | 0.0 | 37.35 |
Sales Turnover | 0.37 | 0.42 |
Return on Assets | 12.28 | 13.29 |
Return on Equity | 12.96 | 14.42 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 22.89 | 15.09 |
Debt/Capital | 0.0 | 0.0 |
Interest Expense | 0.0 | 0.0 |
Interest Coverage | 0.0 | 0.0 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 3.63 | 3.63 |
Div / share | 0.3 | 0.3 |
EPS | 1.18 | 1.25 |
Book value / share | 35.36 | 31.49 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 21430.0 | 11218.0 |
HOLD. UTAH MEDICAL PRODUCTS INC's P/E ratio indicates a significant discount compared to an average of 53.34 for the Computer and Electronic Product Manufacturing subsector and a significant discount compared to the S&P 500 average of 27.95. For additional comparison, its price-to-book ratio of 1.97 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 23.59. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. Upon assessment of these and other key valuation criteria, UTAH MEDICAL PRODUCTS INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UTMD 15.24 | Peers 53.34 | UTMD NA | Peers 44.47 | |||||||||||||||||||||
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. UTMD is trading at a significant discount to its peers. |
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures. Ratio not available. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
UTMD NA | Peers 26.06 | UTMD NA | Peers 1.95 | |||||||||||||||||||||
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential. Ratio not available. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
UTMD 1.97 | Peers 23.59 | UTMD 1.33 | Peers 123.02 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. UTMD is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, UTMD is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
UTMD 5.03 | Peers 14.13 | UTMD -3.94 | Peers 27.20 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. UTMD is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. UTMD significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||